Промомед logo
Промомед PRMD
report update icon

Quarterly report 2026-Q2
added 09-19-2026

Промомед Income Statement 2025-2021 | PRMD

Annual Income Statement Промомед

2025 2024 2023 2022 2021

Revenue

37.6 B 21.5 B 15.8 B 13.5 B 13.2 B

General and Administrative Expenses

7.22 B 3.95 B 2.93 B 3.01 B 2.46 B

Operating Expenses

11.4 B 7.16 B 4.41 B 4.16 B 3.88 B

Interest Expense

4.17 B 2.9 B 1.59 B 740 M 400 M

Depreciation And Amortization

1.4 B 1.1 B 1 B 600 M 400 M

EBITDA

15.3 B 8.23 B 6.28 B 5.95 B 5.03 B

EBITDA Ratio

0.41 0.38 0.4 0.44 0.38

Operating Income

13.7 B 6.9 B 5.6 B 5.35 B 4.62 B

Operating Income Ratio

0.36 0.32 0.35 0.4 0.35

Income Before Tax

7.04 B 2.86 B 2.97 B 3.97 B 3.38 B

Net Income Ratio

0.19 0.13 0.19 0.29 0.26

Earnings Per Share, EPS

33 13 15 19 -

EPS Diluted

33 13 15 19 -

Weighted Average Shares Outstanding

212 M 212 M 200 M 212 M -

All numbers in RUB currency

Quarterly Income Statement Промомед

2026-Q2 2026-Q1 2025-Q4 2025-Q2 2025-Q1

Revenue

15.6 B 7.3 B 24.6 B 8.52 B 4.49 B

General and Administrative Expenses

4.79 B - 4.36 B 2.86 B -

Operating Expenses

8.67 B - 7 B 4.36 B -

Interest Expense

2.52 B - 2.34 B 1.82 B -

Depreciation And Amortization

800 M - 700 M 700 M -

EBITDA

7.68 B - 10.9 B 4.37 B -

EBITDA Ratio

0.492 - 0.443 0.513 -

Operating Income

6.95 B - 10.2 B 3.48 B -

Operating Income Ratio

0.446 - 0.415 0.408 -

Net Income Ratio

0.16 - 0.229 0.164 -

Earnings Per Share, EPS

11.8 - 26.6 6.56 -

EPS Diluted

11.8 - 26.6 6.56 -

Weighted Average Shares Outstanding

212 M 212 M 212 M 212 M 212 M

All numbers in RUB currency

The income statement is one of the three key financial reports of a company Промомед (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Puma Biotechnology Puma Biotechnology
PBYI
$ 9.67 1.68 % $ 484 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
$ 1.49 0.62 % $ 1.95 M usaUSA
Vaxcyte Vaxcyte
PCVX
$ 73.82 30.7 % $ 10 B usaUSA
PDS Biotechnology Corporation PDS Biotechnology Corporation
PDSB
$ 1.2 60.32 % $ 55.7 M usaUSA
Pfizer Pfizer
PFE
$ 27.41 0.02 % $ 156 B usaUSA
Precigen Precigen
PGEN
$ 7.74 4.02 % $ 2.42 B usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 9.8 0.51 % $ 6.75 B niderlandNiderland
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
$ 6.7 1.77 % $ 489 M usaUSA
Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp.
PHIO
$ 0.99 0.6 % $ 5.92 M usaUSA
Pliant Therapeutics Pliant Therapeutics
PLRX
$ 1.03 0.48 % $ 63.2 M usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
$ 2.71 0.37 % $ 213 M israelIsrael
PMV Pharmaceuticals PMV Pharmaceuticals
PMVP
$ 1.78 2.29 % $ 93.5 M usaUSA
Praxis Precision Medicines Praxis Precision Medicines
PRAX
$ 283.56 3.0 % $ 6.38 B usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
$ 0.88 0.04 % $ 570 K israelIsrael
Prelude Therapeutics Incorporated Prelude Therapeutics Incorporated
PRLD
$ 3.77 2.72 % $ 290 M usaUSA
ProQR Therapeutics N.V. ProQR Therapeutics N.V.
PRQR
$ 1.67 2.14 % $ 176 M niderlandNiderland
Prothena Corporation plc Prothena Corporation plc
PRTA
$ 8.27 0.35 % $ 445 M usaUSA
PTC Therapeutics PTC Therapeutics
PTCT
$ 63.65 0.3 % $ 5.06 B usaUSA
Protagonist Therapeutics Protagonist Therapeutics
PTGX
$ 140.63 0.41 % $ 8.94 B usaUSA
Pulmatrix Pulmatrix
PULM
$ 1.48 0.64 % $ 5.41 B usaUSA
PolyPid Ltd. PolyPid Ltd.
PYPD
$ 5.2 0.19 % $ 85 M israelIsrael
Repare Therapeutics Repare Therapeutics
RPTX
- - $ 112 M canadaCanada
uniQure N.V. uniQure N.V.
QURE
$ 22.8 0.39 % $ 1.31 B niderlandNiderland
Rocket Pharmaceuticals Rocket Pharmaceuticals
RCKT
$ 2.61 1.95 % $ 290 M usaUSA
Arcus Biosciences Arcus Biosciences
RCUS
$ 24.74 1.23 % $ 2.66 B usaUSA
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
$ 726.47 0.05 % $ 76 B usaUSA
Replimune Group Replimune Group
REPL
$ 13.15 0.61 % $ 1.22 B usaUSA
Rafael Holdings Rafael Holdings
RFL
$ 1.47 0.65 % $ 43.3 M usaUSA
REGENXBIO REGENXBIO
RGNX
$ 7.76 4.44 % $ 400 M usaUSA
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
$ 47.79 1.36 % $ 860 M usaUSA
Relay Therapeutics Relay Therapeutics
RLAY
$ 19.39 2.27 % $ 3.33 B usaUSA
Avidity Biosciences Avidity Biosciences
RNA
$ 7.97 1.66 % $ 1.1 B usaUSA
Royalty Pharma plc Royalty Pharma plc
RPRX
$ 56.66 0.36 % $ 24.4 B usaUSA
Revolution Medicines Revolution Medicines
RVMD
$ 207.68 0.5 % $ 39.5 B usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
$ 92.45 0.24 % $ 6.01 B usaUSA
Rezolute Rezolute
RZLT
$ 4.33 7.98 % $ 450 M usaUSA
Sana Biotechnology Sana Biotechnology
SANA
$ 2.88 1.21 % $ 729 M usaUSA
Seer Seer
SEER
$ 2.33 3.56 % $ 129 M usaUSA
SIGA Technologies SIGA Technologies
SIGA
$ 3.48 2.96 % $ 249 M usaUSA
Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd.
SLGL
$ 78.95 9.65 % $ 220 M israelIsrael
Silence Therapeutics plc Silence Therapeutics plc
SLN
$ 10.14 0.78 % $ 1.44 B britainBritain
SELLAS Life Sciences Group SELLAS Life Sciences Group
SLS
$ 11.63 3.62 % $ 1.27 B usaUSA
Summit Therapeutics Summit Therapeutics
SMMT
$ 17.27 3.07 % $ 12.9 B britainBritain
Syndax Pharmaceuticals Syndax Pharmaceuticals
SNDX
$ 17.83 1.31 % $ 1.54 B usaUSA
Soligenix Soligenix
SNGX
$ 0.36 0.6 % $ 1.87 M usaUSA
Sanofi Sanofi
SNY
$ 39.51 1.19 % $ 48.2 B franceFrance
Spruce Biosciences Spruce Biosciences
SPRB
$ 45.42 2.1 % $ 34.8 M usaUSA
Spero Therapeutics Spero Therapeutics
SPRO
$ 1.16 4.13 % $ 65 M usaUSA
Sarepta Therapeutics Sarepta Therapeutics
SRPT
$ 17.49 0.7 % $ 1.75 B usaUSA
Scholar Rock Holding Corporation Scholar Rock Holding Corporation
SRRK
$ 43.4 1.41 % $ 4.98 B usaUSA